Document resource
Objectives In SLE an early diagnosis and treatment advances have resulted in improved outcomes, and it is well known that management should aim at remission and, when it is not possible, to a low-disease activity state. Data from literature indicate that 45–70% of patients may achieve remission, while ~80% of patients may reach low disease activity(1). Moreover, even if low dosage of glucocorticoids(GC) is admitted into the definition of remission/LLDAS, the most recent management recommendations have proposed as target the withdrawal of GC(2).The aim of the study was to evaluate the prevalence of patients that met the definition of DORIS remission and/or LLDAS with or without GC, analyzing possible reason in patients that not meet this target.Methods We examined 401 medical charts of patients affected by SLE, who reached our Lupus Clinic from January 2023 to May 2025. SLEDAI-2K, SLICC Damage Index, LLDAS and DORIS were recorded at the last available visit. GC, HCQ, DMARDS, biological therapies were also evaluatedResults Epidemiological features, cumulative clinical manifestations and global ongoing treatment are reported in table 1.Mean SLEDAI-2K was 1.3(±1.9), 350(87.3%) reached the LLDAS, while 314(78.3%) met the DORIS criteria. Comparisons between patients in remission or not are detailed in table 1. Notably, patients meeting DORIS criteria showed lower SLICC-SDI.Among patients who did not achieve DORIS remission, 13(14.9%) required GC>5mg/day; 48(55.2%) had cSLEDAI>0, 10(11.5%) exhibited both cSLEDAI>0 and GC>5mg/day. Lastly, 14(16.1%) showed a PGA>0.5.Globally, DORIS without GC was achieved by 180 (44.9%), whereas the other 134 in DORIS with GC were taking a mean dosage of 3,4mg. In particular, 23(7.3%) were still receiving 5mg/day of GCs. Of these, 3(13%) were tapering GC following a recent flare, 12(52.2%) couldn’t reduce the dose due to symptom recurrence, 6(26.1%) had no recent tapering attempts and 2(12.7%) continued GC for other indications.Abstract PO:05:145 Table 1Conclusions A substantial proportion of long-standing SLE achieved remission, associated with longer disease duration, lower cumulative damage. Persistent low-dose GC highlights the complexity of tapering strategies and suggest that formal remission does not always coincide with GC withdrawal. Personalized management remains essential to optimize long-term outcomes.